Hak J Lee1, Christopher V Barback2,3, Carl K Hoh2,3, Zhengtao Qin2,3, Kareem Kader1, David J Hall2,3, David R Vera4,3, Christopher J Kane1. 1. Department of Urology, University of California, San Diego, La Jolla, California. 2. Department of Radiology, University of California, San Diego, La Jolla, California; and. 3. UCSD Molecular Imaging Program, University of California, San Diego, La Jolla, California. 4. Department of Radiology, University of California, San Diego, La Jolla, California; and dvera@ucsd.edu.
Abstract
The primary objective was to test the ability of a laparoscopic camera system to detect the fluorescent signal emanating from sentinel lymph nodes (SLNs) approximately 2 d after injection and imaging of a positron-emitting molecular imaging agent into the submucosa of the porcine urinary bladder. Methods: Three female pigs underwent a submucosal injection of the bladder with fluorescent-tagged tilmanocept, radiolabeled with both 68Ga and 99mTc. One hour after injection, a pelvic PET/CT scan was acquired for preoperative SLN mapping. Approximately 36 h later, robotic SLN mapping was performed using a fluorescence-capable camera system. After identification of the fluorescent lymph nodes, a pelvic lymph node dissection was completed with robotic assistance. All excised nodal packets (n = 36) were assayed for 99mTc activity, which established a lymph node as an SLN. 99mTc activity was also used to calculate the amount of dye within each lymph node. Results: All of the SLNs defined by the ex vivo γ-well assay of 99mTc activity were detected by fluorescence mode imaging. The time between injection and robotic SLN mapping ranged from 32 to 38 h. A total of 5 fluorescent lymph nodes were detected; 2 pigs had 2 fluorescent lymph nodes and 1 pig exhibited a single lymph node. Four of the 5 SLNs exhibited increased SUVs of 12.4-139.0 obtained from PET/CT. The dye content of the injection sites ranged from 371 to 1,441 pmol, which represented 16.5%-64.1% of the injected dose; the amount of dye within the SLNs ranged from 8.5 to 88 pmol, which was equivalent to 0.38%-3.91% of the administered dose. Conclusion: Fluorescent-labeled 68Ga-tilmanocept allows for PET imaging and real-time intraoperative detection of SLNs during robotic surgery.
The primary objective was to test the ability of a laparoscopic camera system to detect the fluorescent signal emanating from sentinel lymph nodes (SLNs) approximately 2 d after injection and imaging of a positron-emitting molecular imaging agent into the submucosa of the porcine urinary bladder. Methods: Three female pigs underwent a submucosal injection of the bladder with fluorescent-tagged tilmanocept, radiolabeled with both 68Ga and 99mTc. One hour after injection, a pelvic PET/CT scan was acquired for preoperative SLN mapping. Approximately 36 h later, robotic SLN mapping was performed using a fluorescence-capable camera system. After identification of the fluorescent lymph nodes, a pelvic lymph node dissection was completed with robotic assistance. All excised nodal packets (n = 36) were assayed for 99mTc activity, which established a lymph node as an SLN. 99mTc activity was also used to calculate the amount of dye within each lymph node. Results: All of the SLNs defined by the ex vivo γ-well assay of 99mTc activity were detected by fluorescence mode imaging. The time between injection and robotic SLN mapping ranged from 32 to 38 h. A total of 5 fluorescent lymph nodes were detected; 2 pigs had 2 fluorescent lymph nodes and 1 pig exhibited a single lymph node. Four of the 5 SLNs exhibited increased SUVs of 12.4-139.0 obtained from PET/CT. The dye content of the injection sites ranged from 371 to 1,441 pmol, which represented 16.5%-64.1% of the injected dose; the amount of dye within the SLNs ranged from 8.5 to 88 pmol, which was equivalent to 0.38%-3.91% of the administered dose. Conclusion: Fluorescent-labeled 68Ga-tilmanocept allows for PET imaging and real-time intraoperative detection of SLNs during robotic surgery.
Authors: Sean P Stroup; Christopher J Kane; Salman Farchshchi-Heydari; Claude M James; Christopher H Davis; Anne M Wallace; Carl K Hoh; David R Vera Journal: Clin Exp Metastasis Date: 2012-06-20 Impact factor: 5.150
Authors: Ava Hosseini; Jennifer L Baker; Christopher A Tokin; Zhengtao Qin; David J Hall; Dwayne G Stupak; Tomoko Hayashi; Anne M Wallace; David R Vera Journal: J Surg Res Date: 2014-05-10 Impact factor: 2.192
Authors: Nicholas J Hellenthal; Abid Hussain; Paul E Andrews; Paul Carpentier; Erik Castle; Prokar Dasgupta; Jihad Kaouk; Shamim Khan; Adam Kibel; Hyung Kim; Murugesan Manoharan; Mani Menon; Alex Mottrie; David Ornstein; Joan Palou; James Peabody; Raj Pruthi; Lee Richstone; Francis Schanne; Hans Stricker; Raju Thomas; Peter Wiklund; Greg Wilding; Khurshid A Guru Journal: BJU Int Date: 2011-02 Impact factor: 5.588
Authors: Bertram Yuh; Walter Artibani; Axel Heidenreich; Simon Kimm; Mani Menon; Giacomo Novara; Ashutosh Tewari; Karim Touijer; Timothy Wilson; Kevin C Zorn; Scott E Eggener Journal: Eur Urol Date: 2013-05-18 Impact factor: 20.096
Authors: Per-Uno Malmström; Zhi-Ping Ren; Amir Sherif; Manuel de la Torre; Kenneth Wester; Magnus Thörn Journal: J Urol Date: 2002-11 Impact factor: 7.450
Authors: Rutger Mahieu; Gerard C Krijger; F F Tessa Ververs; Remmert de Roos; Remco de Bree; Bart de Keizer Journal: Eur J Nucl Med Mol Imaging Date: 2021-04 Impact factor: 9.236
Authors: Rutger Mahieu; Dominique N V Donders; Gerard C Krijger; F F Tessa Ververs; Remmert de Roos; John L M M Bemelmans; Rob van Rooij; Remco de Bree; Bart de Keizer Journal: Eur J Nucl Med Mol Imaging Date: 2021-12-28 Impact factor: 10.057
Authors: Ravali A Reddy; Ashley S Moon; Stephanie Chow; Lucas Heilbroner; Brooke Howitt; Elisabeth Diver; Oliver Dorigo; Babak Litkouhi; Malte Renz; Amer Karam Journal: Gynecol Oncol Rep Date: 2022-07-30
Authors: Kristen M Anderson; Christopher V Barback; Zhengtao Qin; David J Hall; Carl K Hoh; David R Vera; Michael T McHale Journal: PLoS One Date: 2018-07-02 Impact factor: 3.240